Pfizer to boost Singapore trials by 10%; Vaccine fears causing measles revival;

 @FierceBiotech: Pfizer R&D chief touts 'golden age' of drug discovery. Article | Follow @FierceBiotech

 @JohnCFierce: $25M upfront is the beginning of a beautiful friendship. $50M upfront says you really care. $100M upfront says Pfizer's gone crazy again.| Follow @JohnCFierce

> Pfizer plans to up the number of clinical trials it conducts in Singapore by 10 percent this year as part of it's strategy to focus more on drugs in Asia. Report

> Labopharm has completed a licensing and distribution agreement for once-daily tramadol with Nippon Shinyaku of Japan. Labopharm release

> Dendreon says Varun Nanda has joined the company as senior vice president of global commercial operations, effective April 19, 2010. Nanda most recently served as the senior vice president and global head of oncology at Roche/Genentech, where he led the global product strategy for all oncology molecules, from pre-clinical research through commercialization. Dendreon release

And Finally... In spite of years of research proving otherwise, some parents still misguidedly believe vaccines--such as the measles, mumps and rubella (MMR) shot--can cause autism. And their decision to skip their children's vaccinations are leading to an increasing number of measles outbreaks. Story

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.